Several receptors that mediate apoptosis have been identified, such as Fas and tumor necrosis factor receptor I. Studies of the signal transduction pathways utilized by these receptors have played an important role in the understanding of apoptosis. Here we report the first ligand-receptor pair ± the neuropeptide substance P and its receptor, neurokinin-1 receptor (NK 1 R) ± that mediates an alternative, non-apoptotic form of programmed cell death. This pair is widely distributed in the central and peripheral nervous systems, and has been implicated in pain mediation and depression, among other effects. Here we demonstrate that substance P induces a nonapoptotic form of programmed cell death in hippocampal, striatal, and cortical neurons. This cell death requires gene expression, displays a non-apoptotic morphology, and is independent of caspase activation. The same form of cell death is induced by substance P in NK 1 R-transfected human embryonic kidney cells. These results argue that NK 1 R activates a death pathway different than apoptosis, and provide a signal transduction system by which to study an alternative, non-apoptotic cell death program.
Introduction
The original definition of apoptosis as a form of cell death distinct from necrosis was based on morphological criteria. 1 Genetic studies in C. elegans led to the identification of key components of the apoptotic cell death pathway, including the protease Ced-3.
2 ± 5 However, it has become increasingly clear that the morphological descriptions of apoptosis and necrosis are not adequate to describe all cell deaths. For example, certain developmental cell deaths, such as autophagic' cell death 6 ± 11 and`cytoplasmic' cell death, 6 ,9,12 ± 15 do not resemble apoptosis. Furthermore, neurodegenerative diseases, such as Huntington's disease and amyotrophic lateral sclerosis, demonstrate neuronal cell death that does not fulfil the criteria for apoptosis, 16, 17 but in some cases resembles a recently described form of cell death dubbed`paraptosis'. 18 Ischemia-induced cell deaths may also display a non-apoptotic morphology, referred to as`oncosis'. 19 The biochemical basis for these alternative morphological forms of cell death remains largely unknown. Understanding the mechanisms for these forms would have potentially important implications for the understanding of evolutionary aspects of cell death programs, developmental cell death, neurodegeneration, and cancer therapeutics, and for the design of novel therapeutic agents for diseases featuring these alternative forms of cell death.
Cell death has been divided into two main types: programmed cell death (pcd), in which the cell plays an active role in its own demise, and passive (necrotic) cell death. The pcd observed during development and tissue homeostasis has been classified morphologically into three main types: type 1, also known as nuclear or apoptotic; type 2 or autophagic; and type 3, a non-lysosomal vesiculate degeneration. 9 Apoptosis is the best characterized type of pcd, in which the cells display membrane blebbing, flipping of phosphatidylserine (PS) in the plasma membrane, 20 nuclear fragmentation, and activation of a family of cell-suicide cysteine proteases referred to as caspases (cysteinyl aspartic-specific proteases). 5 , 21 The biochemical activation of apoptosis occurs through two general pathways: the intrinsic pathway, originating from mitochondrial release of cytochrome c and associated activation of caspase-9; and the extrinsic pathway, originating from the activation of cell surface death receptors such as Fas, and resulting in the activation of caspase-8.
can be activated in some cases by Ras, 23 while the molecular activation of type 3 cell death is unknown.
Interest in non-apoptotic forms of pcd has grown recently with the demonstration that the death of neurons in Huntington's disease is neither apoptotic nor necrotic. 16 This work mirrors earlier work also showing non-apoptotic death in a transgenic mouse model of another neurodegenerative disease, amyotrophic lateral sclerosis. 17 Similarly, neuronal cell death in other neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease has not, to date, been shown to be mediated predominantly by apoptosis.
Substance P (SP) is an undecapeptide neurotransmitter belonging to the tachykinin family of peptides, members of which display some similarity in amino acid sequence in their carboxy-termini. SP is an alternatively spliced product of the preprotachykinin A gene (PPTA) that binds with nanomolar affinity to the neurokinin-1 receptor (NK 1 R). NK 1 R is a G-protein coupled receptor that is connected by various second messengers to a wide variety of effector mechanisms to modulate cellular function. Three apparently independent second messenger systems can be activated by G-proteins following ligand binding to NK 1 R: (1) Ca 2+ mobilization from both intra-and extracellular sources via stimulation of phospholipase C; (2) arachidonic acid mobilization via phospholipase A2; and (3) cAMP accumulation via stimulation of adenylate cyclase. 24 An alternative pathway, through interaction with b-arrestin, involves the activation of the MAPK pathway, leading to extracellular signal-regulated protein kinases 1 and 2 (ERKs) activation. 25 The development of specific agonists and antagonists for NK 1 R has supported a role for NK 1 R in numerous biological processes, such as the transmission of pain in the spinal cord. In the CNS it also regulates cardiovascular and respiratory function, and is involved in activating the emetic reflex. NK 1 R also regulates several behavioral responses, and has recently been implicated in depression and schizophrenia. It appears to be involved in a wide variety of functions due to its ability to modulate the release of other neurotransmitters, such as excitatory amino acids. 26 SP also seems to play an important role in pathological states in which neural cell death occurs, such as status epilepticus and ischemia. For example, SP null mice demonstrate resistance to excitotoxin-induced seizures, with an associated reduction in neuronal death. 27 Similarly, treatment with an antagonist for NK 1 R inhibits seizures and reduces kainic acid-induced cell death in the CA1 region of the hippocampus. 28 Furthermore, in a model of focal cerebral ischemia, administration of an NK 1 R antagonist reduced infarct volume and improved neurological function. 29 Taken together, these observations suggest that NK 1 R may be a mediator of cell death in vivo.
In the present work, we studied the ability of SP to induce cell death in primary cultures of hippocampal, cortical and striatal neurons. We found that NK 1 R activates a caspase-independent cell death program that requires new gene expression to occur. Morphologically, it does not resemble apoptosis, since there is no membrane blebbing, nuclear fragmentation or phosphatidylserine translocation.
Expression of NK 1 R in non-neuronal cells converted them into SP-sensitive cells, reproducing the cell death morphology that had been observed in neurons. Ultrastructural analysis of the cells revealed vacuolation and some phagolysosomes, while the plasma and nuclear membranes remained intact. SP-induced death in this system was not prevented by caspase inhibitors, nor by overexpression of Bcl-x L .
These results support the view that apoptosis is not the sole cellular death program, and provide a ligand-receptor pair and associated signal transduction system by which to dissect an alternative, non-apoptotic cell death program.
Results
SP induces cell death in neurons in primary culture via the NK 1 receptor
Studies of the effects of SP on neurons stemmed from our earlier finding that SP fits a biophysical profile generated to allow database searches for pro-apoptotic peptides. 30, 31 Indeed, it was shown that SP induces cytochrome c release in a cell-free system of apoptosis. 31 However, the proapoptotic effect of SP required internalization, since extracellular SP was not toxic to fibroblasts even at millimolar concentrations. Surprisingly, then, it was noted that nanomolar concentrations of SP were neurotoxic in primary cultures of striatal, cortical, and hippocampal neurons, inducing a delayed cell death. All three types of neurons were sensitive to micromolar concentrations of SP 48 h after exposure ( Figure 1A ± G), and to nanomolar concentrations 7 days after exposure ( Figure 1H ). However, the dying cells did not show apoptotic bodies, and instead appeared to be vacuolated ( Figure 1B,D,F) .
The selective toxicity of SP observed with neuronal cells in comparison to fibroblasts could conceivably be explained by a receptor-dependent or receptor-independent mechanism (e.g., a difference in membrane composition and membrane potential between neurons and fibroblasts). Therefore, we assessed the stereospecificity of SP's effect by comparing the sensitivity of cortical neurons to L-SP and D-SP. Only L-SP induced cell death ( Figure 1G ).
The stereospecific neurotoxicity elicited by SP suggested interaction with a receptor. To determine whether NK 1 R is the mediator of the SP-induced neuronal cell death, two different antagonists with relative selectivity for NK 1 R were added to the neuronal cultures along with the SP. The Ltryptophan derivative L-732,138 is a competitive antagonist, 32 and L-733,060 is a non-peptide antagonist. 33 Both molecules completely inhibited SP-induced cell death in striatal cells, as shown in Figure 2A , arguing that SPinduced neurotoxicity is mediated by NK 1 R. Immunostaining of striatal, hippocampal, and cortical neurons showed that all three of these neuronal types express NK 1 R (data not shown).
SP-induced death is neither apoptotic nor necrotic
In order to distinguish between an active cell death program and a passive cell death process, SP-induced neuronal cell death was evaluated in the presence of the transcription inhibitor Actinomycin D and the translation inhibitor Cycloheximide. Both prevented the SP toxicity in cortical and striatal neurons, arguing against its being a passive cellular process ( Figure 2B and data not shown).
To determine whether caspases, the cysteine proteases that mediate apoptosis, are required for SP-induced neuronal cell death, the effects of the broad-spectrum caspase inhibitors zVAD.fmk and Boc-aspartyl.fmk (BAF) were evaluated. Neither had any effect on SP-induced neuronal cell death, indicating that this form of cell death is caspase-independent ( Figure 2B ).
In addition to caspase dependence, other hallmarks of apoptosis include apoptotic body formation, membrane bleb formation, nuclear fragmentation, and loss of the normal asymmetry of phosphatidylserine within the plasma membrane. These were evaluated in neurons undergoing SPinduced cell death. DAPI staining demonstrated no nuclear fragmentation, although some degree of chromatin condensation occurred. As a control, tamoxifen was used to induce apoptosis, and in that case nuclear fragmentation was readily detected (Figure 3 ). Annexin-V staining showed no evidence for phosphatidylserine flipping (data not shown).
Thus SP-induced neuronal death required gene expression, was independent of caspase activation, and showed no evidence of membrane bleb formation, apoptotic body formation, nuclear fragmentation, or loss of phosphatidylserine asymmetry.
NK 1 R is a death receptor that mediates non-apoptotic programmed cell death
As noted above, antagonists of NK 1 R blocked SP-induced neuronal cell death, indicating that NK 1 R mediates this type of cell death. It was conceivable that this cell death may require both NK 1 R and some neuron-specific factor or factors. In order to determine whether NK 1 R-mediated cell death requires neuron-specific factors, we expressed NK 1 R in 293T human embryonic kidney cells, which do not express endogenous NK 1 R. Whereas 293T cells are resistant to SP even at millimolar concentrations, 31 the expression of NK 1 R in 293T cells rendered them sensitive to SP at concentrations of 0.1 nM or greater, displaying the same morphology up to 100 mM (Figures 4A ± F and 10A). It is noteworthy that 0.1 nM is similar to the affinity of the NK 1 R for SP. 24 The morphology of NK 1 R-mediated cell death in 293T cells did not present features typical of apoptosis, but instead resembled the process of NK 1 R-mediated cell death observed in primary neurons. The cells rounded up but demonstrated no bleb formation, apoptotic body formation, cell shrinkage or nuclear fragmentation ( Figure  5A ± I). Instead, electron microscopic analysis revealed swelling and vacuolation (the observed vacuolation of the 293T cells was unlikely to be due to a necrotic process, since the vacuolation preceded membrane permeability to Trypan blue by over 24 h) ( Figure 6 ). Furthermore, Annexin-V staining was again negative in NK 1 R-mediated death of 293T cells ( Figure 7E,F) , whereas controls transfected with a Bax expression construct demonstrated clear bleb formation and Annexin-V staining ( Figure 7G,H) . Similarly, TUNEL (TdT-mediated dUTP Nick-End Labeling) staining to detect DNA fragmentation was negative for NK 1 R-mediated cell death ( Figure 8A,B) , while control cells expressing Bax developed a positive signal ( Figure 8C,D) .
Since SP had been shown to display toxicity toward bacteria and mitochondria, 31 it was still possible that the mediation of SP-induced death by NK 1 R was due to internalization of SP and subsequent mitochondrial toxicity, rather than resulting from the triggering of a signal cascade mediated by NK 1 R. Therefore, neurokinin A and SP 6 ± 11 , which are NK 1 R agonists that do not exhibit mitochondrial toxicity, were evaluated. We observed that these molecules were able to induce cell death as well as SP (data not shown), suggesting that NK 1 R mediates SP-induced neuronal cell death by a mechanism independent of direct mitochondrial damage.
As noted above, the caspase inhibitors zVAD.fmk and BAF did not inhibit NK 1 R-mediated cell death in neurons. We found a similar lack of effect in 293T cells ( Figure 9A ), while the apoptosis induced by over-expression of caspase-8 was completely abolished, indicating that the inhibitors were effective ( Figure 9B ). Accordingly, no hydrolysis of substrates for either`initiator' caspases-1, -2, -8, -9 and 10, or`executioner' caspases-3, -6 and -7 was detected ( Figure 9C ). It has been demonstrated that procaspase-3 is present in 293T cells 34 and that it is activated by the serine protease granzyme B. 35 To ensure that the lack of DEVDase activation was not simply due to the lack of activable pro-caspase-3, we added granzyme B to each cytosolic extract of 293T cells transfected with NK 1 R, treated (or not) with SP. The addition of granzyme B activated the procaspase-3, as shown by a sevenfold increase of DEVDase activity, whereas no significant difference was observed in response to SP stimulation ( Figure 9D ). These results indicate that the lack of DEVD cleavage during SP-induced cell death was not due to the presence of a non-functional procaspase-3. The activation of other endopeptidases was also tested, such as calpains (requiring micromolar or millimolar concentrations of calcium) and the chymotrypsin-like activity of the proteosome, and no significant effect on the rates of substrate hydrolysis was detected. We found further that Bcl-x L expression did not inhibit NK 1 R-mediated cell death (P=0.486 by ANOVA test) ( Figure 10 ).
Discussion
It is becoming increasingly clear that non-apoptotic forms of programmed cell death exist, 9, 18 ,36 yet, in marked contrast to apoptotic pcd, very little is known about the biochemical mechanisms involved in non-apoptotic pcd. The importance of defining these mechanisms has been highlighted by recent descriptions of non-apoptotic cell death in neurodegenerative conditions such as Huntington's disease 16 and amyotrophic lateral sclerosis, 17 coupled with the finding that alternative programs of cell death are not affected by apoptosis inhibitors. 18 Thus, elucidation of the biochemical mechanisms of non-apoptotic forms of pcd may contribute to the development of therapies that modulate the neurodegenerative process.
In the present work we have described the first ligandreceptor pair that mediates a non-apoptotic form of pcd. Since the discovery of Fas-Fas L ± a ligand-receptor pair that mediates apoptotic cell death ± facilitated the identification of apoptotic pathways such as the Fas-FADDcaspase-8 pathway, 37 the identification of the pathway by which NK 1 R mediates non-apoptotic pcd should facilitate the definition of biochemical factors involved in nonapoptotic pcd.
The requirement for gene expression indicates that NK 1 R-mediated cell death is programmatic; however, the lack of nuclear fragmentation, bleb formation, apoptotic body formation, phosphatidylserine flipping, and caspase dependence, as well as the lack of effect of Bcl-x L , all argue against apoptosis as the form of pcd mediated by NK 1 R. The presence of vacuoles also argues against apoptotic pcd, and instead suggests either type 2 (autophagic) or type 3 (non-lysosomal vesiculate) pcd (or a previously undescribed form of pcd). The origin of the vacuoles in type 2 pcd is lysosomal, whereas in type 3 pcd the origin of the vacuoles is the endoplasmic reticulum and mitochondria. Further studies will be required to determine whether NK 1 R-mediated cell death is type 2 or type 3 pcd or a novel type of pcd.
It has been shown previously that SP induces glutamate release in the hippocampus 38 and enhances glutamate responses. 39 Thus, the question arises as to whether the SP-induced neuronal cell death we observed was due to glutamate toxicity. This is unlikely for two reasons: first, it requires approximately 10 days for primary neuronal cultures to become sensitive to receptor-mediated glutamate toxicity, and we observed the SP toxicity during the first 7 days of culture. Second, we were able to reproduce the same morphological features of neuronal cell death in 293T cells that had been transfected with a NK 1 R expression construct, despite the fact that 293T cells do not express glutamate receptors and are not sensitive to receptor-mediated glutamate toxicity. We also excluded the possibility that SP acts as a direct mitochondrial toxic peptide, since other NK 1 R agonists such as NKA or SP 6 ± 11 (which lack direct mitochondrial toxicity) killed as well as SP, while the enantiomer D-SP (which does exhibit mitochondrial toxicity but is not an NK 1 R agonist) had no effect.
A member of the NK 1 R-mediated kinase activation pathway ± (Ras) ± has been implicated previously in caspase-independent pcd. 23 Although further work will be required to characterize the signal pathway involved in NK 1 R-mediated non-apoptotic pcd, preliminary data suggest that a MAPK pathway is involved (data not shown).
The kinetics of neuronal cell death induced by SP and mediated by NK 1 R are relatively slow, with cell death occurring within approximately 2 ± 7 days, depending on the concentration of SP. Since the half-life of SP in solution is only a few minutes and we administered the SP only once at the beginning of each experiment, the long delay in cell death appears to be due to the cellular response rather than any prolonged presence of the SP. This offers a system to study gene expression in neurons that are morphologically normal (during the first days after exposure to SP) yet are committed to pcd.
As noted above, recent work has highlighted neurodegenerative cell death, demonstrating that it fits the criteria for neither apoptosis nor necrosis. 16, 17 Interestingly, the cell death morphologies described in both of these cases ± a transgenic model of amyotrophic lateral sclerosis 17 and Huntington's disease 16 ± featured vacuoles in the dying neurons, suggesting the possibility that a non-apoptotic form of pcd may be involved. Furthermore, it is possible that some of the cell death previously described as necrotic, based on morphology, may be due to an alternative, non-apoptotic program of cell death. It is also noteworthy that, for certain pathological states such as status epilepticus and neuronal ischemia, a burst of SP release has been reported to occur, prior to neuronal cell death. 29, 38, 40 For instance, SP is overexpressed in hippocampal neurons during status epilepticus, and intrahippocampal administration of SP triggers pcDNA3.1 NK1R NK1R+SP
HOECHST anti-NK1R self-sustained status epilepticus, generating a pattern of acute hippocampal damage resembling that known to occur in human epilepsy. 38 Furthermore, in some neurodegenerative diseases, a reduction in SP-immunostaining neurons has been demonstrated in specific brain regions: in the inferior temporal cortex and hippocampus in Alzheimer's disease, and in the pars compacta and pars reticulata of the substantia nigra in both Huntington's and Parkinson's diseases. 40 Unfortunately, there is little information published on the pattern of expression of NK 1 R in these diseases, so that it is currently unclear whether the loss of SP-immunostaining cells in these diseases involves NK 1 R.
In addition to playing a role in cell death, SP has been proposed to function as a neurotrophic factor, so the loss of SP-immunopositive neurons could cause a loss of trophic support rather than simply reflecting neurodegeneration. 40 However, the cells that die are the cells that contain SP, rather than the cells that lack it. Compatible with our results, a previous report suggested a neurotoxic role for SP in hippocampal cells, since it was observed that the addition of SP abrogated a neurotrophic activity displayed by the amyloid b1-40 peptide. 41 Others have also observed a killing activity of SP on proliferating non-neuronal cells. 42 The apparent discrepancy in proposed roles for SP may be explicable by differences in cell type, age and SP concentrations used in different studies. Also, other forms of the NK 1 R have been identified, and although their specific functions remain unknown, 24 it is possible that the different responses to SP observed in the other systems are mediated by different receptor complexes.
In summary, SP-NK 1 R represents the first ligandreceptor pair described that mediates non-apoptotic pcd. These results support the view that apoptosis is not the sole cell death program, and provide a signal transduction system by which to study an alternative, non-apoptotic cell death program. Whether NK 1 R-mediated neuronal cell death plays a role in neurodegenerative disease states remains to be determined; however, it is increasingly clear that apoptosis, at least as classically described, does not represent the major mode of cell death in these diseases. Thus, defining the pathways involved in non-apoptotic forms of pcd may lead to novel therapies for these diseases. 
Materials and Methods

Neuronal primary culture
Primary striatal, cortical and hippocampal cultures were prepared from 17-day-old Sprague ± Dawley rat embryos (B&K, Fremont, CA, USA). The tissue was dissected, minced and trypsinized for 5 min using 0.25% trypsin (Cell Grow). After the addition of 10% horse serum to inhibit the trypsin, the cell suspension was triturated 15 ± 20 times with a 10 ml syringe and centrifuged for 5 min at 8006g. The pellet was resuspended in MEM ± PAK (UCSF Cell Culture facility, San Francisco, CA, USA), supplemented with 2.02 gm glucose, 2 mM of GlutaMax (Life Technologies, Grand Island, NY, USA) and penicillin/ streptomycin (100 U/ml). The suspension was filtered through a 70 mm cell strainer and the final culture medium contained 5% horse serum (Life Technologies). 3 ± 4610 5 cells per cm 2 were seeded onto either poly-D-lysine precoated 8-well chamber slides (Becton-Dickson Labware, Bedford, MA, USA) or 96-well plates pre-coated with 50 mg/ml of poly-D-lysine (Sigma, St. Louis, MO, USA) in water. After 30 min incubation, unattached cells were removed together with the medium and replaced with glucose enriched MEM-PAK plus 5% horse serum (Life Technologies). The cultures were incubated at 378C in 95% air 5% carbon dioxide with 95% humidity. Cultures were used for experiments between day 1 and day 7 when glial contaminants were at a minimum.
SP (SIGMA) 0.1 nM ± 100 mM was added 24 ± 48 h after seeding, in the presence of 2.5% horse serum. When the cultures were maintained for more than 5 days, 10 mM cytosine arabinoside was added for 24 h, beginning 3 days after plating the cells. The following compounds were added at the same time as SP in the indicated experiments: 5 nM L-732,138; 1 nM L-733,060; 1 mg/ml Actinomycin D or 1 mg/ml Cycloheximide. All of these compounds were obtained from SIGMA. zVAD.fmk or BAF was added at 50 mM and obtained from Enzyme System Products, Livermore, CA, USA. 4-Hydroxytamoxifen from SIGMA was added at 50 mM.
Viability was quantified by Trypan blue staining of the total cell population.
Induction of death in transfected human embryonic kidney 293T cells
The full-length (1.2 kb) NK1R cDNA was cloned by RT ± PCR from adult rat hippocampal RNA into the XbaI/EcoRI sites of the vector pcDNA3.1 7 (Invitrogen), using the following oligonucleotides: forward 5'-GGTCTATTGCCCCAAAATGGATAACG-3'; reverse 5'-CTGAATT-CAAGATGGCTAGAGGCATGCC-3'. The mutants were created using the QuickChange strategy (Stratagene, La Jolla, CA, USA), using the following sequences for the oligonucleotides: 5'-GTGGACCTGGCCT-TCGCTCAGGCCTGCATGGCTGCATTC-3' for NK 1 RE78Q mutation and 5'-GGAAATGAAATCCACCCGATACCTCTAGGCATATTCAAGG-CATGC-3' for NK 1 RD342 truncation. Human embryonic kidney 293T cells were grown in high glucose DMEM (Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (SIGMA) and penicillin/streptomycin 100 U/ml (Life Technologies, Grand Island, NY, USA). The cultures were incubated at 378C in 95% air 5% carbon dioxide with 95% humidity. Transient transfection was performed using Superfect (Qiagen) as described by the manufacturer. Briefly, 2610 cells/well were seeded into 35 mm wells 16 h prior to transfection. Superfect : DNA complexes were added at a 5 ml : 2 mg ratio for 3 h; then the medium was replaced and after 24 h SP was added. After 24 ± 48 h addition of SP cell death was quantified as follows: the media containing floating cells were collected and centrifuged 10 min at 20006g, the pellet was resuspended in PBS/Trypan blue and the cells were counted using a hematocytometer. When other compounds were used, they were added at the same time as SP:zVAD.fmk or BAF was added at 50 mM and obtained from Enzyme System Products, Livermore, CA, USA.
Nuclear staining
Either neuronal primary cultures or human embryonic kidney 293T cells were fixed with 4% paraformaldehyde and stained with 0.5 mg/ml DAPI (Molecular Probes) or Hoechst (SIGMA).
NK 1 R immunostaining
Cells were fixed 10 min with 4% paraformaldehyde; permeabilized 10 min with 2% Triton X-100/phosphate-buffered saline (PBS); washed with PBS, blocked 30 min with 4% goat serum/4%BSA/PBS; washed with PBS; incubated 16 h at 48C with a 1 : 500 dilution of anti-NK 1 R (SIGMA); washed with PBS; incubated 30 min with 1 : 10,000 anti-rabbit coupled to FITC or Texas Red (Molecular Probes) and washed with PBS.
Electron microscopy
Human embryonic kidney 293T cells were grown to 50% confluency on poly-L-lysine-coated Thermanox 2 coverslips (13 mm, round, VWRScientific Products) and transfected with NK 1 R expression construct as described above. Pairs of duplicate coverslips were treated with 10 mM SP or vehicle alone for 24 h, and then fixed with 2.0% paraformaldehyde/0.2% glutaraldehyde in 150 mM sodium cacodylate buffer, pH 7.4 (CB) at RT. Fixation was continued at 48C until the cells were washed well and postfixed in 2% osmium tetroxide (OsO 4 ) (Electron Microscopy Sciences). They were reacted with 0.5% tannic acid (Sigma) followed by 1%NaSO 4 , and stained with 5% uranyl acetate in 50% ethanol during dehydration. Cells were flat embedded in Epon 812 between a second Thermanox 2 coverslip, and three or four samples from each sandwich were re-embedded in Epon blocks. En face thin sections were counterstained with uranyl acetate and lead citrate, and examined at 80 kV in a FEI-Philips Tecnai 12 (FEI-Philips, Hillsborough, OR, USA). Digital CCD images (Gatan Bioscan, Livermore, CA, USA) were acquired in Digital Micrograph 1.0 (FEIPhilips) and trimmed in Adobe Photoshop 5.0.
Annexin-V staining
Cells were stained according to the manufacturer's instructions (Clontech). Briefly, cells were washed with binding buffer and incubated with FITC-Annexin-V or EGFP-Annexin-V for 5 ± 10 min and fixed with 4% paraformaldehyde.
TUNEL staining
Cells were fixed 10 min with 4% paraformaldehyde and stained according to the manufacturer's instructions (Promega).
Protease activation during SP-induced cell death
Preparation of cell-free extract for kinetic studies: 293T cells seeded at the density of 2 million cells per 10 cm dish were transfected with NK 1 R cDNA using Lipofectamine 2000 (Gibco) according the instructions provided by the manufacturer. After 24 h 10 nM SP was added to half of the culture dishes. Cells were washed 24 h later with ice-cold PBS and collected with a cell scraper. The cells pelleted at 7006g for 4 min were resuspended in cell lysis buffer at pH 7.4 containing 1 mM dithiothreitol at a ratio of 1 : 1 (v/v). After 30 min on ice the swelled cells were disrupted with 20 strokes using a 27 gauge needle and further spun at 16 0006g for 30 min. The pellet was discarded and the supernatant which represents the cytosolic fraction was aliquoted and stored at 7808C or used in the kinetic studies. The protein concentration was determined using the Bradford assay (Pierce).
Kinetic studies: the proteolytic activities were followed fluorometrically by monitoring AFC or AMC release from 100 mM of the corresponding substrates (Enzyme Systems Products): Caspase-1 like, Ac-YVAD-AFC; caspase-2, Ac-VDVAD-AFC; caspases-3 like, Ac-DEVD-AFC; caspase-6, Ac-VEID-AFC; caspase-8, Ac-IETD-AFC; caspase-9, Ac-LEHD-AFC. Calpain activity was monitored with 100 mM Suc-LY-AFC (succinyl-Leu-Tyr-7-amino-4-methylcoumarin, Enzyme Systems Products) at 5 mM and 5 mM CaCl 2 . The chymotrypsin activity of the proteosome was followed with 100 mM Suc-LLVY-AFC (succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin, Enzyme Systems Products), and cathepsins were assayed using 20 mM Z-FR-AMC (Benzyloxycarbonyl-Phe-Arg-7-amino-4-methylcoumarin, Bachem). A 10 ml aliquot of extract in the presence or absence of SP was added to 90 ml of substrate at the appropriate concentration and pH. The reaction was continuously monitored during 30 min and 378C in a fluorescence microplate reader (Molecular Devices). The instrument was set at excitation and emission wavelengths of 405 and 510 for AFC releasing group, and 370 and 460 nm, for AMC releasing group, respectively. The steady-state hydrolysis rates were obtained from the linear part of the curves.
